JUVEDERM®
Showing all 11 results
-


JUVEDERM® SKINVIVE
$ 359.00 Add To Cart-+

JUVEDERM® ULTRA 2 with Lidocaine
$ 229.00 Add To Cart-+

JUVEDERM® ULTRA 3 with Lidocaine
$ 325.00 Add To Cart-+

JUVEDERM® ULTRA 4 with Lidocaine
$ 329.00 Add To Cart-+

JUVÉDERM® ULTRA PLUS XC
$ 489.00 Add To Cart-+

JUVEDERM® ULTRA SMILE with Lidocaine
$ 255.00 Add To Cart-+

JUVEDERM® VOLBELLA with Lidocaine
$ 379.00 Add To Cart-+

JUVÉDERM® VOLIFT® RETOUCH with Lidocaine
$ 219.00 Add To Cart-+

JUVÉDERM® VOLIFT® with Lidocaine
$ 449.00 Add To Cart-+

JUVÉDERM® VOLUMA® with Lidocaine
$ 359.00 Add To Cart-+

JUVÉDERM® VOLUX® with Lidocaine
$ 399.00 Add To Cart-+Direct Doctor Supply provides access to the complete JUVÉDERM® collection of hyaluronic acid (HA) fillers for licensed aesthetic professionals and approved buyers. Developed by Allergan Aesthetics and now part of AbbVie, JUVÉDERM® includes a broad range of injectable gels designed for facial volume restoration, contour enhancement, wrinkle correction, lip refinement, and skin quality improvement. Built on advanced VYCROSS® and HYLACROSS™ technologies, the JUVÉDERM® portfolio includes products developed for different treatment objectives — from restoring cheek structure and defining the jawline to enhancing lips and improving overall skin smoothness.
With LOT-verified inventory, tracked fulfillment, and temperature-controlled shipping, Direct Doctor Supply helps clinics access authentic JUVÉDERM® products while maintaining reliable supply for their aesthetic practice.
What Is JUVÉDERM®? AbbVie’s HA Filler Collection Explained
JUVÉDERM® is a comprehensive collection of dermal fillers originally developed by Allergan and now owned by AbbVie following its acquisition of Allergan in 2020. The portfolio includes more than ten products built around two key technology platforms — VYCROSS® and HYLACROSS™ — allowing practitioners to select formulations based on different aesthetic goals.
As HA dermal fillers, JUVÉDERM® products use cross-linked sodium hyaluronate, a form of hyaluronic acid designed to attract and retain water within treated areas. This mechanism helps restore facial volume, enhance contours, soften wrinkles and folds, and improve overall skin appearance. The XC formulations also contain lidocaine to support greater patient comfort during treatment.
Manufactured at the Allergan facility in Pringy, France, the JUVÉDERM® range covers multiple aesthetic applications, including cheek and midface restoration, lip enhancement, wrinkle correction, jawline definition, and skin quality improvement. Beyond volumizing treatments, selected products in the portfolio function as skinboosters, helping address hydration and skin smoothness concerns through targeted microinjection techniques.
JUVÉDERM® Product Range – All Products with Clinical Detail
The JUVÉDERM® portfolio includes formulations developed for different areas of facial aesthetics. Each product is designed with specific rheological characteristics, allowing practitioners to choose an option based on the amount of support, flexibility, and correction required.
The collection includes products for:
- Restoring cheek and midface volume
- Enhancing lip shape and definition
- Softening facial folds and wrinkles
- Improving jawline contour
- Supporting skin hydration and smoothness through skinboosters
JUVÉDERM® VOLUMA® XC
VOLUMA® XC is placed deep in the cheek and midface to restore age-related volume loss in adults 21 and over. In the US, the same product is also approved for chin-region augmentation and for correcting moderate to severe temple hollowing in adults.
The gel is VYCROSS® at its most cohesive and highest-elasticity (G’), which gives it the structural lift a softer product cannot deliver. It is the longest-lasting JUVÉDERM® volumizer, with up to 24 months of correction in the cheeks per FDA approval data [1]. Injection is supraperiosteal or deep subcutaneous, using either a needle or a cannula, and the XC suffix means the gel contains lidocaine.
JUVÉDERM® VOLIFT™ / JUVÉDERM® VOLLURE™ XC
VOLIFT™ is the international name and VOLLURE™ XC is the US name for the same VYCROSS® gel. Its indication covers moderate to severe facial wrinkles and folds, including the nasolabial folds and marionette lines.
Compared with VOLUMA®, VOLLURE™/VOLIFT™ sits at a lower G’ with a balanced cohesivity, which is what allows it to soften a fold without leaving the tissue over-corrected or stiff. FDA data show correction persisting up to 18 months in a majority of subjects, with a responder rate of 59% at 18 months in the pivotal VYC-17.5L study [2]. Placement is mid-dermis to deep dermis along the fold line via needle or cannula, and lidocaine is included in the XC formulation.
JUVÉDERM® VOLBELLA® XC
VOLBELLA® XC is the softest and lowest-G’ VYCROSS® gel. Its US approvals cover lip augmentation and correction of perioral (vertical lip) lines in adults 21 and over, and, per an approval announced in 2022, the appearance of infraorbital (undereye) hollows in adults over 21, with Allergan product training required before treating that area [6].
The tuning of the gel is what recommends it for the lip: enough cohesivity to hold shape, but not the volumizing capacity of ULTRA XC. Lip results extend up to 12 months per FDA labeling [3]. Administration is submucosal or intradermal into the lip body and vermilion border, and cannula technique is often used in the perioral area to minimize bruising. As with all XC products, lidocaine is included.
JUVÉDERM® ULTRA XC / JUVÉDERM® ULTRA PLUS XC
The ULTRA line uses HYLACROSS™ technology rather than VYCROSS® and remains the most widely used JUVÉDERM® family globally. ULTRA XC is FDA-approved for lip augmentation in adults 21 and over and for moderate to severe facial wrinkles and folds. ULTRA PLUS XC is FDA-approved for deeper, more severe folds and wrinkles.
In practice, ULTRA XC is the everyday pick when a clinic wants a proven, cost-effective lip filler with real longevity, typically 9–12 months in lips. ULTRA PLUS XC sits deeper for the more marked nasolabial folds. Both products contain lidocaine.
JUVÉDERM® VOLUX® XC
VOLUX™ XC is the newest and highest-G’ product in the VYCROSS® portfolio. In the US, it is FDA-approved for deep injection to improve moderate to severe loss of jawline definition in adults over 21 [4]. Per FDA labeling and AbbVie’s approval announcement, jawline definition results last up to 12 months with optimal treatment [4]. Chin augmentation is a common off-label use in the US market. The on-label chin filler in the US is VOLUMA® XC. In EU/international markets, VOLUX™ is often applied along the jawline, mandibular angle, and chin per CE labeling.
Structurally, VOLUX™ acts as a scaffold that softer products cannot replicate. Placement is deep supraperiosteal or deep subcutaneous, via blunt cannula or needle, and lidocaine is included in the XC version.
JUVÉDERM® VOLITE® / SKINVIVE™ by JUVÉDERM®
VOLITE® is the international name and SKINVIVE™ is the US name for a microinjection skin booster in the VYCROSS® family, engineered for hydration and skin quality rather than volume. In the US, SKINVIVE™ is FDA-approved for improving cheek skin smoothness in adults 21 and over.
Placement is a series of superficial intradermal microdroplets, either by serial puncture or retrograde linear technique, across the face. Neck, décolletage, and hands are common off-label targets. Results typically hold for around six months with maintenance sessions [5].
JUVÉDERM® HYDRATE®
HYDRATE® is a legacy EU/international skin-hydration product based on non-cross-linked or lightly cross-linked HA. It sits alongside VOLITE® in the skin-quality category but with a different formulation profile, and it has never been FDA-approved.
Its role in a JUVÉDERM® protocol is limited to biorevitalization microinjection across the face, neck, and décolletage, and it is chosen by clinics that want to keep hydration treatments inside the same brand family. Availability varies by market, so distribution should be verified with AbbVie or the local distributor before quoting patients.
JUVÉDERM® VOLITE® LIPS
OLITE®’s label covers fine lines and skin hydration in the face, neck, décolletage, and hands. However, published clinical experience documents microdroplet VOLITE® for lip hydration and a subtle “lip gloss” effect in patients who want smoother lip skin without added volume. On-label lip augmentation options in the JUVÉDERM® range remain VOLBELLA® XC and ULTRA XC.
Where an injector chooses VOLITE® off-label for the lip, administration is superficial intradermal microdroplet via serial puncture or, preferably, cannula to reduce bruising and intravascular risk. This is an off-label use and appropriate only for trained, licensed injectors.
JUVÉDERM® ULTRA 3 / ULTRA 4
The ULTRA 3 and ULTRA 4 references are EU/international HYLACROSS™ SKUs. ULTRA 3 is the moderate-lines and lip-volume workhorse comparable to ULTRA XC, though some markets sell it without lidocaine. ULTRA 4 is the thicker gel used for deeper folds and stronger volume correction, roughly comparable to ULTRA PLUS XC.
These SKUs are typically selected for cost reasons or where the XC versions are unavailable. Injection depth follows viscosity: ULTRA 3 is intradermal for lips and moderate folds, ULTRA 4 is deep subcutaneous for nasolabial folds and severe wrinkles. Lidocaine content varies by market, so the specific formulation should be confirmed against the label.
JUVÉDERM® VOLUMA® – Non-XC / EU Version
A lidocaine-free VOLUMA® is available in EU/international markets for injectors who prefer to run their own anesthesia protocol with topical products or nerve blocks. The gel is the same VYCROSS® formulation as VOLUMA® XC, and the cheek and midface indications are identical. Injection depth and technique mirror the XC version.
JUVÉDERM® VOLBELLA® – Non-XC / EU Version
The non-XC VOLBELLA® is the same VYCROSS® gel supplied without lidocaine in EU/international markets. It is used for the same lip augmentation and perioral-line indications as VOLBELLA® XC and is chosen by injectors who apply topical or nerve-block anesthesia separately.
Buy JUVÉDERM® Wholesale – Comparison With Other HA Fillers
Selecting an HA dermal filler often depends on more than the product name alone. Practitioners typically consider factors such as gel technology, treatment indication, tissue behavior, clinical evidence, product availability, and the type of aesthetic outcome they want to achieve.
JUVÉDERM® competes with several established dermal filler brands, each with its own formulation approach and product portfolio. The comparisons below highlight key differences between JUVÉDERM® and other commonly used HA fillers.
JUVÉDERM® vs BELOTERO®
BELOTERO® uses Cohesive Polydensified Matrix (CPM) technology, a formulation approach designed for smooth integration within superficial tissue layers. It is commonly associated with treatments involving fine lines and delicate facial areas.
JUVÉDERM® offers a broader HA portfolio, including products designed for cheeks, lips, folds, jawline definition, and skinboosters. The range allows practitioners to select different formulations within one product family based on treatment depth and correction goals.
The decision between these brands depends on the specific indication, desired correction, and practitioner preference.
JUVÉDERM® vs REVANESSE®
REVANESSE®, made by Prollenium in Canada, is marketed on tolerability, particularly low post-injection swelling in the lips. REVANESSE® LIPS+ is the most discussed product in that line.
Against JUVÉDERM®, REVANESSE® is a narrower shortlist: fewer indications, less range depth, and a shorter clinical track record for lip work than ULTRA XC. Clinics chase REVANESSE® either on price or on the swelling profile for particular patients. JUVÉDERM® is the pick where the single-brand full-face protocol matters more than syringe price on a given day.
JUVÉDERM® vs Restylane®
Restylane® and JUVÉDERM® represent two of the most recognized HA dermal filler families worldwide. While both are based on hyaluronic acid, their technologies differ.
Restylane® products use NASHA® and XpresHAn Technology™, which are designed for different levels of firmness, flexibility, and tissue integration. JUVÉDERM® uses VYCROSS® and HYLACROSS™ technologies, offering a range of formulations developed for volume restoration, contouring, lip enhancement, wrinkle correction, and skin quality improvement.
For practitioners, the choice often depends on the treatment objective. Some indications may favor firmer structural support, while others may benefit from a smoother, more cohesive gel designed for natural movement and integration.
JUVÉDERM® vs STYLAGE®
STYLAGE® from Laboratoires VIVACY uses IPN-Like cross-linking and includes mannitol, an antioxidant intended to blunt post-injection edema and extend HA longevity by neutralizing free radicals. That mannitol addition is STYLAGE®’s main differentiator versus JUVÉDERM®.
STYLAGE® runs a broad EU catalogue from fine lines to deep volume and lip augmentation, but longevity data are stronger for VYCROSS® (VOLUMA® at up to 24 months in the cheek is the reference), and STYLAGE® has no US FDA approval. For EU practitioners, the trade-off usually comes down to price and the mannitol argument versus JUVÉDERM®’s brand recognition and evidence depth.
JUVÉDERM® vs TEOSYAL®
TEOSYAL® from Teoxane in Switzerland is best known for RHA® (Resilient Hyaluronic Acid), a technology engineered for dynamic areas of the face. RHA® gels are designed to stretch with expression and recover, which is a validated advantage in perioral, nasolabial, and other high-movement zones where JUVÉDERM® does not have equivalent movement-tuned engineering.
For static cheek volume and longevity, VOLUMA® at up to 24 months typically outperforms comparable TEOSYAL® products. For lips, TEOSYAL® PURESENSE KISS (CE-marked) and RHA KISS (FDA-approved) sit alongside ULTRA XC and VOLBELLA®. Under the eyes, TEOSYAL® PURESENSE REDENSITY II is Teoxane’s dedicated tear-trough product with strong European data. In the US, VOLBELLA® XC carries an approved indication for infraorbital hollows [6].
JUVÉDERM® vs SAYPHA®
SAYPHA® from Croma Pharma in Austria is a CE-marked HA range with SAYPHA® FILLER, SAYPHA® RICH, and SAYPHA® VOLUME covering fine lines, volume restoration, and deep implantation. Some SAYPHA® versions include lidocaine. It is not FDA-approved and is priced as a cost-competitive European alternative.
On brand recognition, clinical evidence depth, and FDA breadth, JUVÉDERM® remains clearly ahead. SAYPHA® is a reasonable EU option where price and origin are the deciding factors. Both are HA-based and reversible with hyaluronidase.
How Long Does JUVÉDERM® Last? Treatment Areas and Safety
Duration across the collection varies by product and treatment area. VOLUMA® reaches up to 24 months in the cheeks [1]. VOLLURE™/VOLIFT™ improvement extends up to 18 months in a majority of subjects, with a 59% responder rate at 18 months in the pivotal VYC-17.5L study [2]. VOLBELLA® provides up to 12 months in the lips [3]. ULTRA XC lip results typically hold 9–12 months. VOLUX™ delivers jawline definition results for up to 12 months with optimal treatment [4]. SKINVIVE™/VOLITE® runs around six months with maintenance sessions [5]. Individual response varies with metabolism, product volume, and treatment area.
The treatment map covers most of the aesthetic face: lip volume and perioral lines, cheek and midface volume restoration, jawline structure, nasolabial and marionette folds, temple hollowing (per US labeling), infraorbital hollows via VOLBELLA® XC in the US [6], and skin-quality microinjection across the cheeks and, off-label, the neck, décolletage, and hands.
JUVÉDERM® products have established safety data across CE-marked and FDA-approved indications. Common side effects are typically mild and short-lived: redness, swelling, pain, bruising, and tenderness at the injection site. Pigmentation disorders are uncommon. The more serious risk with any HA filler is unintended intravascular injection, which can produce vascular occlusion. That risk is technique-dependent, and injections should be performed by clinicians with strong facial anatomy knowledge and complication management training.
Where to Buy JUVÉDERM® Wholesale Online
Maintaining a consistent supply of authentic dermal fillers is essential for aesthetic practices that schedule treatments around patient appointments. Direct Doctor Supply provides access to JUVÉDERM® products with fulfillment support designed to help licensed professionals manage their inventory needs.
Practitioners can order JUVÉDERM® online through Direct Doctor Supply and access a complete range of products, including options for facial volume restoration, lip enhancement, wrinkle correction, contouring, and skin quality treatments.
Every order includes LOT-verified authentic products, tracked fulfillment, and temperature-controlled shipping designed to help protect product integrity throughout delivery. Flexible ordering options, volume-based savings, and account support help clinics maintain reliable access to the products they use regularly.
Whether building treatment plans for individual patients or managing ongoing clinic demand, Direct Doctor Supply provides a streamlined way to source JUVÉDERM® products from a trusted supplier.
Frequently Asked Questions
What does the JUVÉDERM® collection include?
JUVÉDERM® is a family of hyaluronic acid injectables made for facial volumizing, contouring, lip enhancement, wrinkle correction, and skin-quality treatments.
Who is behind the JUVÉDERM® brand?
JUVÉDERM® was developed by Allergan Aesthetics, which became part of AbbVie following its 2020 acquisition of Allergan.
How does SKINVIVE™ fit into the JUVÉDERM® range?
SKINVIVE™ focuses on cheek skin smoothness and hydration rather than adding facial volume. Internationally, the product is known as VOLITE®.
What JUVÉDERM® options are intended for lip treatments?
ULTRA XC is used when added lip volume is the goal, while VOLBELLA® XC is designed for softer enhancement and perioral lines.
Is it possible to adjust or dissolve JUVÉDERM® filler?
Yes. Because JUVÉDERM® fillers contain hyaluronic acid, a trained clinician can use hyaluronidase when dissolution or correction is clinically appropriate.
Do all JUVÉDERM® formulations contain lidocaine?
No. US-approved XC formulations contain lidocaine, while certain non-XC products supplied in international markets may be lidocaine-free.
What reactions can occur after JUVÉDERM® injections?
Temporary swelling, redness, bruising, tenderness, or discomfort can occur. More serious complications, including vascular occlusion, are uncommon but require prompt clinical management.
Can practitioners buy JUVÉDERM® through Direct Doctor Supply?
Licensed practitioners and consumers can order JUVÉDERM® through Direct Doctor Supply with LOT-verified inventory, tracked fulfillment, and support for bulk and repeat orders.
Disclaimer
All content on this website is intended for informational purposes and does not constitute medical advice.
Citations
[1] Callan, Peter et al. “Efficacy and safety of a hyaluronic acid filler in subjects treated for correction of midface volume deficiency: a 24 month study.” Clinical, cosmetic and investigational dermatology vol. 6 81-9. 20 Mar. 2013, doi:10.2147/CCID.S40581
[2] Dayan, Steven et al. “Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds.” Aesthetic surgery journal vol. 40,7 (2020): 767-777. doi:10.1093/asj/sjz200
[3] Raspaldo, Hervé et al. “Lip and Perioral Enhancement: A 12-Month Prospective, Randomized, Controlled Study.” Journal of drugs in dermatology : JDD vol. 14,12 (2015): 1444-52.
[4] U.S. Food and Drug Administration. “JUVÉDERM® VOLUX™ XC (P110033/S065).” U.S. Food and Drug Administration, 2022, www.fda.gov/medical-devices/recently-approved-devices/juvederm-volux-xc-p110033s065.
[5] U.S. Food and Drug Administration. “SKINVIVE™ by JUVÉDERM® (P110033/S059).” U.S. Food and Drug Administration, 2023, www.fda.gov/medical-devices/recently-approved-devices/skinvive-juvederm-p110033s059.
[6] AbbVie. “FDA Approves JUVÉDERM® VOLBELLA® XC for Undereye Hollows.” AbbVie News Center, 8 Feb. 2022, news.abbvie.com/2022-02-08-FDA-Approves-JUVEDERM-R-VOLBELLA-R-XC-For-Undereye-Hollows.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.



